Oxford Endovascular

Oxford Endovascular is a MedTech spin-out from the University of Oxford that develops innovative neurovascular devices to treat brain aneurysms. The company's flagship product, OxiFlow, is a next-generation flow-diverter stent developed using "origami engineering" and laser-cut Nitinol. This technology allows the device to be placed more accurately and safely than existing treatments, reducing the risk of complications and improving patient outcomes. Oxford Endovascular is currently advancing OxiFlow toward first-in-human clinical trials, supported by significant venture capital funding and grants. The company aims to address a global market for brain aneurysm treatments valued at over $1 billion.